
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Naproxcinod
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Nicox SA
Deal Size : Inapplicable
Deal Type : Inapplicable
Nicox Updates on Fera Pharmaceuticals’ Continuing Evaluation of Naproxcinod
Details : Naproxcinod, a Cyclooxygenase-Inhibiting Nitric Oxide (NO)-Donating (CINOD) naproxen, is a non-steroidal anti-inflammatory product candidate engineered to release NO and naproxen, originally discovered and developed by Nicox.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 30, 2021
Lead Product(s) : Naproxcinod
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Nicox SA
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Naproxcinod
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Nicox SA
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Naproxcinod is a nonsteroidal anti-inflammatory product candidate engineered to release NO and naproxen, originally discovered and developed by Nicox. Fera will evaluate naproxcinod as a potential adjuvant treatment for patients with COVID-19 infection.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 11, 2020
Lead Product(s) : Naproxcinod
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Nicox SA
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Hydrocortisone
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Recipient : Koffler Vision Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Hydrocortisone Ophthalmic Ointment 0.5% for Treatment of Allergic Conjunctivitis
Details : Hydrocortisone is a Steroid drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Conjunctivitis, Allergic.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
May 23, 2013
Lead Product(s) : Hydrocortisone
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Recipient : Koffler Vision Group
Deal Size : Inapplicable
Deal Type : Inapplicable
